Experience of using the local combination product containing miconazole and metronidazole for the treatment of bacterial vaginosis and vulvovaginal candidiasis in pregnant women

Bitsadze, Victoria; Radetskaya, L. S.; Радецкая, Л С

doi:10.26442/2079-5696_18.6.56-60

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Біцадзе і Л.С. Радецької (2016) встановило дуже низьку частоту рецидивування після лікування БВ на тлі використання препарату Нeo-Пенотран® Форте у вагітних [67]. Автори пов'язують це з тим, що метронідазол, певно, не викликає пригнічення нормальної лактобактеріальной флори.…”

Section: г і н е к о л о г і яunclassified

“…Отримані дані свідчать про те, що своєчасне й ефективне лікування вагітних (з ІІ триместра) з БВ і КВВ препаратом Нeo-Пенотран® Форте запобігає несприятливим наслідкам вагітності та знижує ризик передчасних пологів, пов'язаний з вагінальної інфекцією [67].…”

Section: г і н е к о л о г і яunclassified

“…Для топічних лікарських форм метронідазолу, у тому числі вагінальних супозиторіїв Нeo-Пенотран ® Форте, оптимальним визнано лікувальний курс тривалістю не менше 7 днів [56,60,63,65,67].…”

Section: г і н е к о л о г і яunclassified

See 2 more Smart Citations

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Мамчур

Дронов

2021

RHW

View full text Add to dashboard Cite

One of the key and strategically important problems of modern gynecology both around the world and in Ukraine is infectious and inflammatory diseases (IVD) of the lower genital tract: according to various estimates, back in the 90s of the last century, this diagnosis was made in about 40 % of patients in gynecological hospitals. Over the first decade of the 21st century, the incidence rate of genital IVI increased 1.4 times in 18–24-year-old patients, and 1.8 times in 25–29-year-old patients. At the same time, the costs of diagnostics and treatment have increased, which reach 50-60% of all costs for the provision of gynecological care to the population.In the structure of gynecological morbidity, the indicator of the number of patients with infectious and inflammatory diseases of the genital area continues to occupy a leading position in terms of frequency in the population, amounting to 60.4-65.0%, however, information from different authors regarding their true prevalence is very contradictory. So, according to the materials of the 33rd European Congress of the International Union against for Sexually Transmitted Infections (IUSTI-Europe), bacterial vaginosis (BV) occurs in 12-80% of women, vulvovaginal candidiasis – VVC (at least one episode in life) - in 75%, aerobic vaginitis (AV) – in 15-25% [8]. According to other authors, the prevalence of BV is 24-30%, VVC – 9.7-11.7%, nonspecific (aerobic) vaginitis – 5.0-23.7%.Combined drugs Neo-Penotran® Forte and Gainomax have a high safety profile, which is due to the unique features of the pharmacokinetics and pharmacodynamics of their components. This determines the advantages in the speed of bactericidal action over other antibacterial and antimycotic agents. These drugs are highly effective in the local treatment of BV and vulvovaginal infections, reaching 98.5% in some nosologies.The effectiveness and safety of the use of Neo-Penotran® Forte and Gainomax in the treatment of infections of the female genital area served as the basis for their inclusion in standard treatment regimens according to indications, and their use is regulated by the normative documents of the Ministry of Health of Ukraine.

show abstract

Section: г і н е к о л о г і яunclassified

See 1 more Smart Citation

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Мамчур

Дронов

2021

RHW

View full text Add to dashboard Cite

show abstract

Vaginal discharge syndrome. Problem with many unknowns

Татарчук¹,

Калугина

Petrova³

et al. 2020

View full text Add to dashboard Cite

The main reason for visiting an obstetrician-gynecologist is the vaginal discharge syndrome (VDS) of infectious etiology. The most common causes of infectious vaginitis wich are identifed by European researchers are bacterial vaginosis (BV), aerobic vaginitis, vulvovaginal candidiasis and mixed infections. Treatment of VDS is a serious problem not only because of the pathogens’s resistance and frequent recurrences, but especially due to the COVID-19 pandemic which can complicate further patient`s examination for determination of infectious agent and the choice of individual approach to etiotropic therapy.Purpose of study: to investigate the structure of causes of pathological vaginal discharge in Ukrainian women, as well as assess the compliance and effectiveness of their treatment.Methods: 472 doctors of women's consultation centres, gynecological hospitals and centers of reproductive medicine from 23 regions of Ukraine were enrolled in multi-center study of vulvovaginal infections management. During the study, which lasted from August to December 2019, were examined 45,295 patients aged 18 to 59 years who complained for pathological vaginal discharge.Results: analysis of the structure of nosologies that caused VDS showed that the examined patients were most often diagnosed with BV (41.1%), colpitis of mixed etiology (26.59%) and vulvovaginal candidiasis (19.22%), trichomoniasis was confirmed in 8.44%. The interviewed gynecologists preferred topical therapy in 95,99% cases of BV and colpitis of mixed etiology. Topical combined medications were prescribed in 85,21% of cases, monoforms – in 14.79%. Among the combined vaginal dosage forms the combination of metronidazole 750 mg /miconazole 200 mg was preferred in 48.81% of cases with clinical efficacy 87.1% in patients with BV and 86,9% in women with mixed infection. Normalization of the vaginal biocenosis was observed in 93.50% of the examined patients. The study demonstrated the safety, good tolerability and compliance of patients to therapy with the combined medications metronidazole 750 mg / miconazole 200 mg in vaginal suppositories.Conclusion: BV, colpitis of mixed etiology and vulvovaginal candidiasis are predominated in structure of main causes of VDS in Ukraine. In the treatment of VDS, priority is given to vaginal forms with the most compliant (89.8%) regimen: once a day for a short period (7 days). The obtained high bacteriological (93.50%) and clinical (86,9%) efficacy of therapy of BV and vaginal mixed infections with the combined drug metronidazole 750 mg / miconazole 200 mg allows to recommend it as the drug of choice.

show abstract

Features pathogenetic therapy of vaginal infections during pregnancy

et al. 2019

View full text Add to dashboard Cite

Vaginal infections occupy an important place in the structure of obstetric-gynecological morbidity. Bacterial vaginosis, trichomoniasis and vulvovaginal candidiasis are the most common infectious causes of vaginitis. Foreign and domestic studies indicate a high frequency of adverse obstetric and neonatal outcomes with this pathology: premature termination of pregnancy, placental insufficiency, fetal growth retardation, chorioamnionitis, postpartum suppurative inflammatory diseases and other complications. Patients with ischemic-cervical insufficiency should be assigned to the group at high risk of developing the above complications. The mixed vaginal infections detected in them require the rehabilitation of the birth canal and the elimination of possible pathogens in a short time. In this regard, timely diagnosis and rational treatment of vaginal infection will reduce the frequency of complications of pregnancy, childbirth, the postpartum period, and neonatal morbidity.

show abstract

Experience of using the local combination product containing miconazole and metronidazole for the treatment of bacterial vaginosis and vulvovaginal candidiasis in pregnant women

Cited by 3 publications

References 0 publications

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Vaginal discharge syndrome. Problem with many unknowns

Features pathogenetic therapy of vaginal infections during pregnancy

Contact Info

Product

Resources

About

Experience of using the local combination product containing miconazole and metronidazole for the treatment of bacterial vaginosis and vulvovaginal candidiasis in pregnant women

Cited by 3 publications

References 0 publications

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of ​​today

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of ​​today

Vaginal discharge syndrome. Problem with many unknowns

Features pathogenetic therapy of vaginal infections during pregnancy

Contact Info

Product

Resources

About

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today

Combined drugs in local therapy of infectious vulvovaginitis are a priority area of today